- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.09. | Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno | ||
| 24.09. | Fujifilm Biotechnologies cuts ribbon on $3.2B antibody facility in NC | ||
| 24.09. | Generics makers to sell Gilead's Yeztugo at $40 a year under deals with Gates Foundation, others | ||
| 24.09. | Big Pharma's backlash against Britain continues as Lilly CEO Ricks blasts UK on drug pricing, investment | ||
| 24.09. | Vertex secures all-star assist for Journavx, signing up NBA's Jayson Tatum for pain drug promotion | ||
| 24.09. | In potential $1.1B deal, Glenmark grabs certain rights to Hengrui's ADC rival to Enhertu | ||
| 24.09. | Biogen plots resubmission after FDA turns down high-dose Spinraza in SMA, requests more production info | ||
| 23.09. | Trust, satisfaction in pharma slipping among Gen Z, millennials: survey | ||
| 23.09. | FDA hands warning letter to J&J vaccine subsidiary over stopper issues, spotty reporting at Korean plant | ||
| 23.09. | Eli Lilly picks Houston to build $6.5B API manufacturing facility | ||
| 23.09. | Sobi surpasses Roche in rare disease patient groups' reputation rankings | ||
| 23.09. | Moderna says updated mNEXSPIKE induces strong immune response against rising COVID-19 strain | ||
| 23.09. | Celltrion snaps up Lilly's N.J. drug substance plant for $330M in tariff mitigation move, pledges to retain employees | ||
| 23.09. | Catalent moves into new global HQ as Novo sale nears one-year anniversary | ||
| 23.09. | FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site | ||
| 22.09. | FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data | ||
| 22.09. | In Trump's 'answer' to autism, health officials to warn against Tylenol during pregnancy, propose potential treatment: WaPo | ||
| 22.09. | In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy | ||
| 22.09. | Exact Sciences scares up spooky season Cologuard campaign starring Matthew Lillard | ||
| 22.09. | With new FDA nod in ulcerative colitis, J&J's Tremfya becomes 1st IL-23 med with IV and subQ options across IBD treatment | ||
| 19.09. | Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection | ||
| 19.09. | Takeda scientists tackle Mount Fuji to advocate for patients in need of plasma-derived therapies | ||
| 19.09. | CDC 'strongly' backs Gilead's HIV PrEP Yeztugo, but advocacy groups say access barriers remain | ||
| 19.09. | Novo's once-weekly combo drug for type 2 diabetes scores EU endorsement | ||
| 19.09. | 'Bombardment of spam' lands Eli Lilly in hot water with UK marketing watchdog |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .